Poly(2-oxazoline) and poly(2-oxazine)-based nanomedicines: Advancements, opportunities and challenges
Authors:
Open Access
- 17 March 2026
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114838
Abstract
No abstract availableKeywords
Funding Information
- Australian Research Council (IH220100017)
- Australian Research Council (FT190100572)
- National Health and Medical Research Council (2019056)
This publication has 276 references indexed in Scilit:
- Impact of Drug Conjugation Site and Corona Chemistry on the Therapeutic Activity of Polymer Nanorod – Drug ConjugatesAdvanced Healthcare Materials, 2024
- Substituting Poly(ethylene glycol) Lipids with Poly(2‐ethyl‐2‐oxazoline) Lipids Improves Lipid Nanoparticle Repeat DosingAdvanced Healthcare Materials, 2024
- Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid TumorsAdvanced Science, 2023
- Bioactive Synthetic PolymersAdvanced Materials, 2021
- Poly(2‐oxazoline)‐ and Poly(2‐oxazine)‐Based Self‐Assemblies, Polyplexes, and Drug Nanoformulations—An UpdateAdvanced Healthcare Materials, 2021
- Drug Delivery Systems Based on Poly(2‐Oxazoline)s and Poly(2‐Oxazine)sAdvanced Therapeutics, 2019
- Chemical Design of Non‐Ionic Polymer Brushes as Biointerfaces: Poly(2‐oxazine)s Outperform Both Poly(2‐oxazoline)s and PEGAngewandte Chemie International Edition, 2018
- Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional TreatmentJAMA, 2011
- Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential AlternativesAngewandte Chemie International Edition, 2010
- Poly(2‐oxazoline)s: A Polymer Class with Numerous Potential ApplicationsAngewandte Chemie International Edition, 2009